ArticlesFirst-line treatment with zoledronic acid as compared with CLODRONIC ACID (cas 10596-23-3) in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
-
Add time:08/16/2019 Source:sciencedirect.com
SummaryBackgroundBisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies. We aimed to establish whether bisphosphonates can affect clinical outcomes in patients with multiple myeloma.
We also recommend Trading Suppliers and Manufacturers of CLODRONIC ACID (cas 10596-23-3). Pls Click Website Link as below: cas 10596-23-3 suppliers
Prev:Determination of impurities in CLODRONIC ACID (cas 10596-23-3) by anion-exchange chromatography
Next:ArticlesEffects of zoledronic acid versus CLODRONIC ACID (cas 10596-23-3) on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- X-ray diffraction study of bisphosphonate metal complexes: Mg, Sr and Ba complexes of (dichloromethylene)bisphosphonic acid P,P′-dibenzoyl anhydride08/20/2019
- X-ray diffraction study of polymeric Mg complexes of CLODRONIC ACID (cas 10596-23-3)08/19/2019
- Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel partial amides of CLODRONIC ACID (cas 10596-23-3)08/18/2019
- ArticlesEffects of zoledronic acid versus CLODRONIC ACID (cas 10596-23-3) on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial08/17/2019
- Determination of impurities in CLODRONIC ACID (cas 10596-23-3) by anion-exchange chromatography08/15/2019
- Clinical efficacy of CLODRONIC ACID (cas 10596-23-3) in horses diagnosed with navicular syndrome: A field study using objective and subjective lameness evaluation08/14/2019
-
Health and Chemical more >